Sanchez-Niño Maria Dolores, Sanz Ana Belen, Ihalmo Pekka, Lassila Markus, Holthofer Harry, Mezzano Sergio, Aros Claudio, Groop Per-Henrik, Saleem Moin A, Mathieson Peter W, Langham Robert, Kretzler Matthias, Nair Viji, Lemley Kevin V, Nelson Robert G, Mervaala Eero, Mattinzoli Deborah, Rastaldi Maria Pia, Ruiz-Ortega Marta, Martin-Ventura Jose Luis, Egido Jesus, Ortiz Alberto
Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Fundación Renal Iñigo Alvarez de Toledo, Madrid, Spain.
J Am Soc Nephrol. 2009 Feb;20(2):353-62. doi: 10.1681/ASN.2008020194. Epub 2008 Oct 8.
Although metabolic derangement plays a central role in diabetic nephropathy, a better understanding of secondary mediators of injury may lead to new therapeutic strategies. Expression of macrophage migration inhibitory factor (MIF) is increased in experimental diabetic nephropathy, and increased tubulointerstitial mRNA expression of its receptor, CD74, has been observed in human diabetic nephropathy. Whether CD74 transduces MIF signals in podocytes, however, is unknown. Here, we found glomerular and tubulointerstitial CD74 mRNA expression to be increased in Pima Indians with type 2 diabetes and diabetic nephropathy. Immunohistochemistry confirmed the increased glomerular and tubular expression of CD74 in clinical and experimental diabetic nephropathy and localized glomerular CD74 to podocytes. In cultured human podocytes, CD74 was expressed at the cell surface, was upregulated by high concentrations of glucose and TNF-alpha, and was activated by MIF, leading to phosphorylation of extracellular signal-regulated kinase 1/2 and p38. High glucose also induced CD74 expression in a human proximal tubule cell line (HK2). In addition, MIF induced the expression of the inflammatory mediators TRAIL and monocyte chemoattractant protein 1 in podocytes and HK2 cells in a p38-dependent manner. These data suggest that CD74 acts as a receptor for MIF in podocytes and may play a role in the pathogenesis of diabetic nephropathy.
尽管代谢紊乱在糖尿病肾病中起着核心作用,但对损伤的次级介质有更深入的了解可能会带来新的治疗策略。在实验性糖尿病肾病中,巨噬细胞移动抑制因子(MIF)的表达增加,并且在人类糖尿病肾病中已观察到其受体CD74的肾小管间质mRNA表达增加。然而,CD74是否在足细胞中传导MIF信号尚不清楚。在这里,我们发现2型糖尿病和糖尿病肾病的皮马印第安人中肾小球和肾小管间质CD74 mRNA表达增加。免疫组织化学证实了临床和实验性糖尿病肾病中肾小球和肾小管CD74表达增加,并将肾小球CD74定位到足细胞。在培养的人足细胞中,CD74表达于细胞表面,被高浓度葡萄糖和肿瘤坏死因子-α上调,并被MIF激活,导致细胞外信号调节激酶1/2和p38磷酸化。高糖也诱导人近端肾小管细胞系(HK2)中CD74的表达。此外,MIF以p38依赖的方式诱导足细胞和HK2细胞中炎症介质TRAIL和单核细胞趋化蛋白1的表达。这些数据表明CD74在足细胞中作为MIF的受体起作用,并且可能在糖尿病肾病的发病机制中起作用。